Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.8.3525

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis  

Zhao, Jing-Yi (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Ma, Xue-Lei (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Li, Yan-Yan (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Zhang, Bing-Lan (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Li, Min-Min (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Ma, Xue-Lei (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Liu, Lei (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.8, 2014 , pp. 3525-3531 More about this Journal
Abstract
Objective: Fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) is a new technique for identifying different malignant tumors using different uptake values between tumor cells and normal tissues. Here we assessed the diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer by pooling data of existing trials in a meta-analysis. Methods: PubMed/MEDLINE, Embase and Cochrane Central Trials databases were searched and studies published in English relating to the diagnostic value of FDG-PET for testicular cancer were collected. The summary receiver operating characteristic (SROC) curve was used to examine the FDG-PET accuracy. Results: A total of 16 studies which included 957 examinations in 807 patients (median age, 31.1 years) were analyzed. A meta-analysis was performed to combine the sensitivity and specificity and their 95% confidence intervals (CIs), from diagnostic odds ratio (DOR), positive likelihood ratios (PLR), negative likelihood ratio (NLR). SROC were derived to demonstrate the diagnostic accuracy of FDG-PET for testicular cancer. The pooled sensitivity and specificity were 0.75 (95% confidence interval (CI), 0.70-0.80) and 0.87 (95% CI, 0.84-0.89), respectively. The pooled DOR was 35.6 (95% CI, 12.9-98.3). The area under the curve (AUC) was 0.88. The pooled PLR and pooled NLR were 7.80 (95% CI, 3.73-16.3) and 0.31 (95% CI, 0.23-0.43), respectively. Conclusion: In patients with testicular cancer, 18F-FDG-PET demonstrated a high SROC area, and could be a potentially useful tool if combined with other imaging methods such as MRI and CT. Nevertheless, the literature focusing on the use of 18F-FDG-PET in this setting still remains limited.
Keywords
$^{18}F$-FDG-PET; testicular cancer; diagnosis; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Uzel EK, Ekmekcioglu O, Elicin O, Halac M & Uzel OE (2013). Is FDG -PET-CT a valuable tool in prediction of persistent disease in head and neck cancer. Asian Pac J Cancer Prev, 14, 4847-51.   과학기술학회마을   DOI   ScienceOn
2 Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM & Kleijnen J (2003). The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol, 3, 25.   DOI   ScienceOn
3 Wilson CB, Young HE, Ott RJ et al (1995). Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med, 22, 508-13.   DOI
4 Sanchez D, Zudaire JJ, Fernandez JM et al (2002). 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int, 89, 912-6.   DOI   ScienceOn
5 Nichols CR (1998). Testicular cancer. Curr Probl Cancer, 22, 187-274.   DOI   ScienceOn
6 Oechsle K, Hartmann M, Brenner W et al (2008) [18F] Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol, 26, 5930-5.   DOI   ScienceOn
7 Rohren EM, Turkington TG & Coleman RE (2004). Clinical applications of PET in oncology. Radiology, 231, 305-32.   DOI   ScienceOn
8 Siekiera J, Malkowski B, Jozwicki W et al (2012). Can we rely on PET in the follow-up of advanced seminoma patients? Urol Int, 88, 405-9.   DOI   ScienceOn
9 Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA & Oyen WJ (2002). The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int, 89, 549-56.   DOI   ScienceOn
10 Stephens AW, Gonin R, Hutchins GD & Einhorn LH (1996). Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol, 14, 1637-41.
11 Tsatalpas P, Beuthien-Baumann B, Kropp J et al (2002). Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int, 68, 157-63.   DOI   ScienceOn
12 Karapetis CS, Strickland AH, Yip D, Steer C & Harper P G (2003). Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Intern Med J, 33, 427-35.   DOI   ScienceOn
13 Kollmannsberger C, Oechsle K, Dohmen B M et al (2002). Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer, 94, 2353-62.   DOI   ScienceOn
14 Huddart R A (2003). Use of FDG-PET in testicular tumours. Clin Oncol (R Coll Radiol), 15, 123-7.   DOI   ScienceOn
15 Johns Putra L, Lawrentschuk N, Ballok Z et al (2004). 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology, 64, 1202-7.   DOI   ScienceOn
16 Lassen U, Daugaard G, Eigtved A et al (2003). Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging, 30, 396-402.   DOI
17 Lewis DA, Tann M, Kesler K et al (2006). Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. J Clin Oncol, 24, e54-5.   DOI
18 McGee S (2002). Simplifying likelihood ratios. J Gen Intern Med, 17, 646-9.
19 Moses LE, Shapiro D & Littenberg B (1993). Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med, 12, 1293-316.   DOI   ScienceOn
20 Mutlu H, Buyukcelik A, Erden A et al (2013). Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev, 14, 3743-6.   과학기술학회마을   DOI   ScienceOn
21 Deeks JJ, Macaskill P & Irwig L (2005). The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol, 58, 882-93.   DOI   ScienceOn
22 Devesa SS, Blot WJ, Stone BJ et al (1995). Recent cancer trends in the United States. J Natl Cancer Inst, 87, 175-82.   DOI   ScienceOn
23 Ganjoo KN, Chan RJ, Sharma M & Einhorn LH (1999). Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol, 17, 3457-60.
24 Hain S F (2005). Positron emission tomography in uro-oncology. Cancer Imaging, 5, 1-7.   DOI   ScienceOn
25 Hain SF, O’Doherty MJ, Timothy AR et al (2000). Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer, 83, 863-9.   DOI   ScienceOn
26 Halfpenny W, Hain SF, Biassoni L et al (2002). FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer, 86, 512-6.   DOI   ScienceOn
27 Hanley JA & McNeil BJ (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143, 29-36.   DOI
28 Hinz S, Schrader M, Kempkensteffen C et al (2008). The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol, 179, 936-40; discussion 940.   DOI   ScienceOn
29 Hofer C, Kubler H, Hartung R, Breul J & Avril N (2001). Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol, 40, 481-7.
30 Hoekstra OS, Ossenkoppele GJ, Golding R et al (1993). Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med, 34, 1706-10.
31 Chen YK, Yeh CL, Tsui CC et al (2011). F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med, 36, 553-9.   DOI   ScienceOn
32 Becherer A (2011). PET in testicular cancer. Methods Mol Biol, 727, 225-41.   DOI   ScienceOn
33 Becherer A, De Santis M, Karanikas G et al (2005). FDG PET is superior to CT in the prediction of viable tumour in postchemotherapy seminoma residuals. Eur J Radiol, 54, 284-8.   DOI   ScienceOn
34 Bokemeyer C, Kollmannsberger C, Oechsle K et al (2002) Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [ (18)F]FDG PET. Br J Cancer, 86, 506-11.   DOI   ScienceOn
35 Cremerius U, Wildberger JE, Borchers H et al (1999). Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Urology, 54, 900-4.   DOI   ScienceOn
36 Cremerius U, Effert PJ, Adam G et al (1998). FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med, 39, 815-22.
37 Czernin J (2002). Clinical applications of FDG-PET in oncology. Acta Med Austriaca, 29, 162-70.   DOI   ScienceOn
38 Dalal PU, Sohaib SA & Huddart R (2006). Imaging of testicular germ cell tumours. Cancer Imaging, 6, 124-34.   DOI
39 de Wit M, Brenner W, Hartmann M et al (2008). [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours:results of the German multicentre trial. Ann Oncol, 19, 1619-23.   DOI   ScienceOn
40 De Santis M, Becherer A, Bokemeyer C et al (2004). 2-18fluorodeoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma:an update of the prospective multicentric SEMPET trial. J Clin Oncol, 22, 1034-9.   DOI   ScienceOn
41 Akbulut Z, Canda AE, Atmaca AF et al (2011). Is positron emission tomography reliable to predict post-chemotherapy retroperitoneal lymph node involvement in advanced germ cell tumors of the testis? Urol J, 8, 120-6.
42 Albers P, Bender H, Yilmaz H et al (1999). Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology, 53, 808-11.   DOI   ScienceOn
43 Albers P, Weissbach L, Krege S et al (2004). Prediction of necrosis after chemotherapy of advanced germ cell tumors:results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol, 171, 1835-8.   DOI   ScienceOn
44 Antoch G, Saoudi N, Kuehl H et al (2004). Accuracy of wholebody dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors:comparison with CT and PET. J Clin Oncol, 22, 4357-68.   DOI   ScienceOn
45 Bachner M, Loriot Y, Gross-Goupil M et al (2012). 2-(1)(8)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol, 23, 59-64.   DOI   ScienceOn
46 Saunders CA, Dussek JE, O’Doherty MJ & Maisey MN (1999). Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg, 67, 790-7.   DOI   ScienceOn
47 Yetisyigit T, Babacan N, Urun Y et al (2014). Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors. Asian Pac J Cancer Prev, 15, 831-5.   과학기술학회마을   DOI   ScienceOn